Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
AAN calls on all neurology patients, caregivers to participate in 2012 Neuro Film Festival

AAN calls on all neurology patients, caregivers to participate in 2012 Neuro Film Festival

UCLA program helps improve seniors' self-perceived memory

UCLA program helps improve seniors' self-perceived memory

New insights into Lafora disease

New insights into Lafora disease

PREVENT licenses Amorfix's ProMIS to develop vaccines against misfolded prion diseases

PREVENT licenses Amorfix's ProMIS to develop vaccines against misfolded prion diseases

HH&S, CDC announce eight finalists for 2011 Sentinel for Health Awards

HH&S, CDC announce eight finalists for 2011 Sentinel for Health Awards

Researchers identify molecule that can stop the formation of amyloid fibrils

Researchers identify molecule that can stop the formation of amyloid fibrils

Yale scientists synthesize huperzine A to combat Alzheimer's

Yale scientists synthesize huperzine A to combat Alzheimer's

MR spectroscopy reveals biochemical changes in brains of people at risk for Alzheimer's

MR spectroscopy reveals biochemical changes in brains of people at risk for Alzheimer's

Scientists discover genetic switch to prevent neurodegenerative diseases

Scientists discover genetic switch to prevent neurodegenerative diseases

HHS selects Mayo Clinic physician to chair advisory council on Alzheimer's

HHS selects Mayo Clinic physician to chair advisory council on Alzheimer's

New mouse brain atlas provides insight into how genes work in cerebral cortex

New mouse brain atlas provides insight into how genes work in cerebral cortex

Free Alzheimer's disease conference to take place on Sept. 17

Free Alzheimer's disease conference to take place on Sept. 17

People with Down syndrome have diminished optokinetic, vestibular reflexes

People with Down syndrome have diminished optokinetic, vestibular reflexes

KFDA approves IND for DP-b99 Phase III MACSI stroke study in Korea

KFDA approves IND for DP-b99 Phase III MACSI stroke study in Korea

First international conference on developmental, translational and clinical pharmacogenomics

First international conference on developmental, translational and clinical pharmacogenomics

Seeing provides the big picture, but exploration burns it into memory

Seeing provides the big picture, but exploration burns it into memory

Scientists identify molecular pathway that plays a key role in stress-related DNA damage

Scientists identify molecular pathway that plays a key role in stress-related DNA damage

New report: Molecular imaging market to reach $6 billion by 2015

New report: Molecular imaging market to reach $6 billion by 2015

Risk of Parkinson's disease increases with traumatic brain injury and exposure to pesticide paraquat

Risk of Parkinson's disease increases with traumatic brain injury and exposure to pesticide paraquat

Cellular pathology of Lou Gehrig’s disease discovered

Cellular pathology of Lou Gehrig’s disease discovered

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.